GE HealthCare Technologies stock
GEHCNASDAQGE HealthCare Technologies Inc., HealthcareISIN US36266G1076
69Score 69 out of 100, Neutral
Price and trend
82 / 100
Price history
+13% in one yearThe chart shows daily closes over 4 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 18% above it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 75).
The price is 6.3% below its 52-week high. Largest decline in 4 years: 37% (March 2024 to April 2025).
Chart figures for advanced users
- SMA 50$70.06
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$69.90
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$59.49
- The lowest closing price of the last twelve months.
- Resistance$88.16
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- GE HealthCare Technologies Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $37.35B, is number 7 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $20.63B (up 4.8% year on year) and earnings of $2.08B (up 4.6%).
- For fiscal 2026, analysts expect on average revenue of $21.87B (up 6%) and adjusted earnings per share of $5.02 (up 9.5%).
Show more
- MEQIRI Score 69 out of 100 (Neutral): rank 159 of 714 in Healthcare, median 53.
- The P/E is 17.3 (Medical (Devices) median 29, own median of recent years 17.9).
- Our model puts fair value at $121.66, with the price 32% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 32% below the fair value of $121.66.Valuation 77
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and momentum, while growth holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 68 to 69.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $93.58 and expensive above $173.80 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $104.63 (cash-flow model) and $138.69 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.2%. At 10.2% the fair value would be $112.96, at 8.2% it would be $134.38.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 6.9% on the twelve months before. Revenue has grown solidly since 2019, at about 4% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 40%, operating 13%, net 10%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 3 Feb 2027in 83 days
- Last reported
- 28 Oct 2026EPS reported $1.34 (expected $1.20)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $5.02+1.9%
- Revenue
- $21.87B+0.7%
- Earnings per share
- $5.52+1.5%
- Revenue
- $22.94B+0.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +7.5%GE HealthCare raised its full year 2026 guidance: organic revenue growth now about 4%, EBIT margin 15.5% to 15.7%, adjusted EPS $4.95 to $5.05 and free cash flow above $1.6 billion.
“We now expect organic revenue growth of approximately 4% adjusted EBIT margin in the range of 15.5% to 15.7%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $641,800 in total.
- Lobo KevinPurchase
22 May 2026, Board
- Shares
- 10,000
- Price
- $64.18
- Value
- $641,800
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at GE HealthCare Technologies
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- StrykerSYK $121.36B70
- Boston ScientificBSX $65.41B63
- Edwards LifesciencesEW $60.84B76
- Siemens HealthineersSHL.DE $54.2B65
- Shenzhen Mindray Bio-Medical Electronics300760.SZ $32.12B75
- DexComDXCM $29.97B78
- Koninklijke PhilipsPHIA.AS $29.51B56
- Terumo4543.T $23.31B76
ETFs that hold GE HealthCare Technologies
Held by 114 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| VanEck Morningstar US ESG Wide Moat UCITS ETFGMVM | 2.64% | 0.49% | €368.7M |
| Global X S&P 500 Covered Call UCITS ETF IncXY7D | 1.90% | 0.45% | €203.27M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.80% | 0.49% | €318.39M |
Show 5 more
| Amundi US Tech 100 Equal Weight UCITS ETF DR USDWEBA | 1.60% | 0.07% | €340.27M |
| UBS Factor MSCI USA Prime Value Screened UCITS ETF hEUR accUBUW | 0.58% | 0.28% | €127.84M |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.56% | 0.12% | €1.34B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.56% | 0.15% | €592.11M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.56% | 0.15% | €3.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Sep 2026)
- Valuation signal Undervalued since 11 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.